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tically significant for both feet (p0.001). Hyperkeratosis of both feet, evaluated by
the doctor, significantly improves after 4 weeks of treatment. The efficacy score
measured by the patient is 16.4 ( 4.8) on inclusion. Measured under the same
conditions, it is 7.7 ( 3.2) at 4 weeks. The difference is statistically significant
(p0.001). Treatment compliance is good since 89% confirm that they respected the
dosage, a trend confirmed by the fact that 94% of subjects say that they are satisfied
with the product.CONCLUSIONS: By means of a validated score (XAS) and a patient
evaluation scale, the efficacy of Pedimed in treating the diabetic foot is confirmed.
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OBJECTIVES: The objective of this study was to estimate a prevalence of diabetes
mellitus (DM) among patients with micro- and macrovascular complications in
Poland, like angina pectoris, myocardial infarction (MI), stroke, lower limb isch-
emia, end-stage renal disease (ESRD), and their consequences like heart failure,
visual disorders or amputations. METHODS: The estimation was based on obser-
vational studies, which were identified by searching medical databases and Polish
registries. Publications were selected in a specific order, to ensure that included
data are the most representative for Polish population. Firstly, studies conducted in
Polish settings were included and, if no reliable publications were found, European,
non-European Caucasian and other (not specified) population were analyzed. Pop-
ulation based registries were considered as the most appropriate type of data.
When no registry was available systematic reviews of observational studies were
included. If systematic review was not available – data from clinical studies were
taken into account. RESULTS: According to polish registries, DM was present in
28% of patients with non-ST-elevation MI, 20% of patients with ST-elevation MI,
22% of patients with unstable angina and 22% patients with ESRD. The results of
two studies regarding Polish population indicate that 15.3% of patients with stable
angina pectoris suffer from DM. The results of studies coming from European coun-
tries identified by literature search showed that DM was diagnosed in 26.2% of
patients with heart failure, 21.5% of patients with stoke, 40% of patients hospital-
ized for peripheral artery disease, 52.8% of patients with lower-extremity amputa-
tion and 67.1% of patients with non-traumatic amputations. Diabetes was present
in 34.9%, 9.4% and 7.1% of patients with retinopathy, vision disorders and blindness
respectively. CONCLUSIONS:DM often co-exists with vascular disorders in Poland.
It affects 15% of patients with macrovascular complications and more than 20% of
patients with microvascular complications.
PDB20
A1C VARIABILITY AND THE RISK OF DEVELOPING NEW DIABETES FOR THE
HEALTHY ADULTS IN JAPAN
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OBJECTIVES: To evaluate the effect of A1C variability on the risk of developing new
diabetes in healthy adults in Japan. METHODS: Population-based, retrospective
cohort from 2005 to 2008 in Tokyo, Japan. In healthy adults not taking diabetes
medication and with lower than 6.5 of HbA1c at baseline, we measured annually
the serum HbA1c and calculated the annual visit-to-visit variability. RESULTS: At
baseline, 14,764 people (49% female) with a mean age of 50 years old (SD: 12 years,
range: 23 to 92), a mean fasting plasma glucose (FPG) level of 98.4 mg/dl (SD: 9.3
mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %) had annual check-ups over 4
years. Using the multivariate logistic regression, the A1C variability (odds ratio
(OR): 7.8 for highest quantile interval ( 0.16%)) versus the lowers quantile (0.08
%), 95%CI: 4.8 – 12.8) and the baseline A1C (OR: 43.3 for group with 6.0 – 6.4 % of A1C
versus with 5.0 %, 95% CI: 10.4 – 181.4) were independently predictive of new
diabetes after adjusting for the other potential risk factors. FPG (OR: 1.1, 95%CI: 1.1
– 1.2) and Smoker (OR: 1.6, 95%CO: 1.2 – 2.3) also significantly related to develop the
new diabetes.CONCLUSIONS:Visit-to-visit variability in A1C independently added
to the baseline A1C in predicting the risk of developing new diabetes for the healthy
adults.
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OBJECTIVES: Beta cells in the pancreas are responsible for secreting insulin in
response to increases in blood glucose. Proinsulin C-peptide (C-peptide), co-se-
creted with insulin, is a marker for beta cell function. C-peptide levels at type 1
diabetes (T1D) diagnosis and rate of decline (ROD) post diagnosis are important
when evaluating the potential beta cell-preserving therapies to maintain better
glycemic control and reduce complications. Because little is known about factors
that affect C-peptide levels at diagnosis and ROD, we aimed to summarize known
factors. METHODS: We conducted a systematic review of literature in PubMed
(English only) from 1987 using the following key words alone and in combination:
type 1 diabetes, c-peptide, rate of decline, concentration, epidemiology, residual
beta cell function, diagnosis. Additionally articles were identified from the refer-
ence lists of selected journal articles. RESULTS: The review indicated that: 1) De-
cline of beta-cell function begins years before T1D diagnosis; 2) At diagnosis stim-
ulated C-peptide concentrations range from 0.320.26 pmol/mL (meanSD) to
1.40.8 pmol/mL (meanSD); 3) Stimulated C-peptide ROD can range from -0.00 to
-0.01 pmol/mL/month; 4) Lower C-peptide concentrations at diagnosis are partly
explained by younger onset age, time since diagnosis, genetic factors and a high-
titer presence of islet cell autoantibodies; and 5) Intensive therapy to treat T1D of
3 insulin injections daily reduces the C-peptide level after 1 year by 0.210.03
pmol/mL versus 0.150.02 pmol/mL for less intensive treatment of 1-2 injections.
CONCLUSIONS: Understanding the factors that influence C-peptide ROD may help
researchers develop strategies which address heterogeneity of response to ther-
apy, resulting in improved glycemic control and reduction in complications such as
ketoacidosis, neuropathy or nephropathy. Including parameters for C-peptide and
its ROD in pharmacoeconomic models may help estimate the burden of these
complications in T1D, and help quantify the benefits of preserving beta cells.
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OBJECTIVES: The safety and efficacy of exenatide BID (exenatide) compared to
insulin glargine (glargine) has been studied in clinical trials and use of exenatide
has been associated with reductions in A1C and weight. This study examined the
clinical outcomes of exenatide versus glargine in patients with type 2 diabetes in a
‘real-world’ ambulatory care setting. METHODS: A retrospective analysis was con-
ducted using the General Electric electronic medical record database to select ex-
enatide (n4,494) and glargine (n5,424) cohorts. These cohorts were propensity-
score matched to control for baseline demographic, clinical, and resource use
variables (2,683 matched pairs). Matched cohorts were compared using paired t-
tests and nonparametric tests as appropriate. The effectiveness endpoints were
changes in A1C (primary endpoint), weight, body mass index (BMI), blood pressure
(BP), lipid levels, and hypoglycemia rates. RESULTS: The matched exenatide and
glargine cohorts had comparable age (58 vs. 58 years), females (55% vs. 53%), and
baseline clinical characteristics. In a 12-month follow-up period, the exenatide
cohort achieved greater mean (SD) reduction in A1C (-0.66% [1.5] versus -0.41%
[1.7], P0.01), weight (-2.6 [6.8] vs. -0.2 [9.2] kg, P0.01), BMI (-0.9 [2.6] versus
-0.1 [2.7] kg/m2, P0.01), and systolic BP (-1.8 [17] vs. -0.3 [18] mmHg, P0.01).
More exenatide-treated patients reached the A1C goal of7% (46% vs. 36%, P0.01).
There were no clinically significant differences in diastolic BP, lipid levels, and
hypoglycemia rates between cohorts. CONCLUSIONS: Exenatide-treated patients
experienced significantly greater reductions in A1C, weight, BMI, and systolic BP
than the glargine cohort. These results demonstrated the clinical effectiveness of
exenatide compared to glargine in a large, diverse, ‘real-world’ patient population
treated in the ambulatory care setting.
Diabetes/Endocrine Disorders – Cost Studies
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OBJECTIVES: According to HTA reports regarding long-acting insulin analogues
(LAIA) these drugs should be reserved for use in selected diabetic patients only. In
line with recent knowledge LAIA in Poland are planned to be reimbursed in frame-
work of therapeutic programme (LAIA-TP). This study assess the impact of this
decision on public health-payers budget. METHODS: The analysis was perfomed
using modelling technique, based on systematic review of LAIA, Polish epidemio-
logic and costing data. Two scenarios were compared: (A) LAIA not reimbursed, (B)
LAIA reimbursed for patients with episodes of severe hypoglicaemia (after 6
months reimbursement continued only in patients successfully treated). In each
scenario annual costs of insulinotherapy, monitoring and tretament of hypoglicae-
mia were estimated in 3-years time horizon. Model was run by having the current
patient cohort progress through the model accompanied by the addition each year
of a new cohort of eligible patients. Extreme scenario sensitivity analyses were
performed. RESULTS: The expected number of diabetic patients eligible for LAIA
would be 12,611 in the 1st year, and each year 661 “new” patients will meet inclu-
sion criteria. Only 25% patients with type 1 and 30% patients with type 2 diabetes
will be successfully treated with LAIA. The introduction of LAIA-TP is expected to
increase public-payers expenditure in years 1st -3th by 12,168,582, 7,972,737 and
8,321,552 PLN, respectively (1 PLN0.25 EURO, 2011). Such an increase in cost would
be associated with acquisition cost of LAIA and would be only partially compen-
sated by lower costs of monitoring and treatment of hypoglicaemia. Depending on
assumptions about population and effectiveness of LAIA the additional expendi-
tures of public payer varies between 11,295,941- 8,962,648 PLN, 7,219,765-9,627,449
PLN and 7,556,552-10,505,485 PLN in 1st, 2nd and 3rd year, respectively.
CONCLUSIONS: Budget impact analysis indicates that reimbursement of LAIA-TP
seems to be affordable to the budget holder.
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OBJECTIVES: Hyperglycaemia is a frequent condition in hospitalizations for acute
conditions, not always correlated with a previous presence of diabetes. Patients
with hyperglycaemia experiment a worse prognosis, with increased mortality,
complications and a longer hospital stay than normal ones. Several evidences in
A475V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
literature demonstrate that the outcome can also be influenced by the insulin
regimen used by the hospital. Objective of this study is the Budget Impact Analysis
(BIA) of the hospital use of aspart insulin with respect to other rapid insulin alter-
natives available on the market. METHODS: All the hospitalizations with evidence
of hyperglycaemia in one year in Italy were considered. Four alternatives were
evaluated: 1) aspart insulin; 2) lispro insulin; 3) glulisine insulin; 4) human insulin.
Administration of insulin regimen (basal rapid), length of hospital stay and inci-
dence of hypoglycaemic events were simulated. The rates of hypoglycaemic events
with rapid insulin alternatives, and the prolongation of hospital stay caused by
such an event were derived from international literature. Only differential costs
among alternatives were accounted for, i.e. purchase and administration of rapid
insulin and management of hypoglycaemic events. Epidemiologic and healthcare
resource consumption data derived from Italian published sources. Current prices
and tariffs were applied in the perspective of the hospital. RESULTS: A total of 7.7
million hospitalizations of adult patients in one year were considered, of which
23.6% (1.8 million) with evidence of hyperglycaemia. Total costs with the aspart
insulin resulted: €7.8 million for insulin, €7.4 million for administration and €507.0
million for hypoglycaemic events management (total: €522.2 million). Total costs
with the other rapid insulin alternatives were higher (range: 4% to 37.2%).
CONCLUSIONS: Aspart insulin has a listed purchasing cost in Italy equal or higher
than alternatives, but the BIA indicates that its adoption can yield savings for the
hospital, being the hypoglycaemic events management the main cost driver.
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OBJECTIVES: Among patients with type-2 diabetes mellitus (T2DM) previously
treated with only OADs, to evaluate real-world differences in clinical and economic
outcomes following initiating basal analog insulin therapy via disposable pen with
either glargine (GLA-P) or detemir (DET-P). METHODS: The MarketScan databases
(2006–2010) were used to identify patients with T2DM aged 18–79 years and receiv-
ing 1 OAD, but no insulin before initiation of GLA-P or DET-P. Patients had con-
tinuous health plan enrollment for 6 months prior to (baseline) and 1 year after
GLA-P or DET-P initiation (follow-up). Propensity score matching 1:1 was applied to
match the two patient cohorts using baseline demographic and clinical factors.
Study outcomes included treatment persistence and adherence, hypoglycemia-
related medical events, and healthcare utilization and costs during the follow-up.
RESULTS: The 2 matched cohorts (n5771 each, mean age 54, female 49%) were
well balanced for baseline characteristics (all P0.1). During follow-up, patients
initiating GLA-P were more likely to be persistent (42.9 vs. 38.4%, P0.001) and
adherent (adjusted medication possession ratio 0.70 vs. 0.67, P0.001) with treat-
ment versus those initiating DET-P. The average daily study drug consumption
dose was 33U in both cohorts. Fewer GLA-P than DET-P users returned to OAD-only
(18.6 vs. 20.5%, P0.011). Hypoglycemia-related medical events were similar (0.7 vs.
1.0%, P0.093), while the mean number of hypoglycemia-related emergency room
(ER) or hospital events per patient was lower for GLA-P (0.006 vs. 0.012, P0.010).
The diabetes-related pharmacy costs were similar for GLA-P and DET-P ($2,465 vs.
$2513, P0.155), as were the total health care costs ($16,058 vs. $16,209, P0.69).
CONCLUSIONS: Real-world T2DM patients initiating insulin therapy via disposable
pen with GLA-P were more likely to persist and adhere with treatment compared
with patients initiating with DET-P. GLA-P users had fewer ER-/hospital-related
hypoglycemia events, while costs were similar for both.
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OBJECTIVES: The aim of this analysis was to estimate the long-term incremental
clinical and cost outcomes associated with exenatide once weekly (EQW) versus
sitagliptin therapy in type 2 diabetes patients in the UK. Data from DURATION-2; a
phase 3, multinational, randomised, double-blind clinical trial in 491 patients with
type 2 diabetes previously treated with metformin were used. After 26 weeks,
patients receiving EQW (n160) had a significantly greater LS mean HbA1c reduc-
tion (-1.6% versus -0.9%, respectively) and weight reduction (-2.3 kg versus -0.8 kg,
respectively) than patients who received sitagliptin (n166). METHODS: A previ-
ously published and validated diabetes model (IMS CORE Diabetes Model) was used
to make 50 year projections of clinical and cost outcomes based on DURATION-2
baseline patient characteristics and study results. Costs were derived from pub-
lished sources and expressed in 2010 UK Pounds. A discount rate of 3.5 % was
applied to both costs and outcomes. Various sensitivity analyses were performed.
RESULTS: EQW treatment was projected to improve quality-adjusted life expec-
tancy by 0.22 quality-adjusted life years (QALYs) (95% confidence interval 0.12 to
0.32) versus sitagliptin. Total direct medical costs associated with EQW were pro-
jected to be higher over patient lifetimes than with sitagliptin (difference of £1405,
95% confidence interval £444 to £1982), due to higher drug acquisition costs, which
were partially offset by the lower incidence of diabetes-related complications dur-
ing treatment with EQW, and hence cost of treating. The projected incremental
cost effectiveness ratio (ICER) was £6418 per QALY gained. Results of the sensitivity
analysis showed that the ICER was influenced by a reduction in time horizon,
decrease in EQW benefits on HbA1c and increased time on EQW. CONCLUSIONS:
Projected from the DURATION-2 trial, EQW can be considered cost-effective versus
sitagliptin in the UK setting from the NHS perspective. The results were robust to
sensitivity analyses.
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OBJECTIVES: The aim of this analysis was to estimate the cost-effectiveness of
exenatide once weekly (EQW) versus exenatide BID therapy, two formulations of
the same glucagon-like peptide-1 receptor agonist molecule, in type 2 diabetes
patients in the UK. Pooled data from DURATION-1 and DURATION-5, phase 3, ran-
domised, open label clinical trials in 295 and 252 patients respectively, were used.
EQW was associated with greater LS mean HbA1c reduction (-1.7% versus -1.2%,
respectively, p0.001) and weight reduction (-2.9 kg versus -2.4 kg, respectively,
p0.126). METHODS: A previously published and validated diabetes model (IMS
CORE Diabetes Model) was used to make 50 year projections of clinical and cost
outcomes based on pooled DURATION-1 and 5 baseline patient characteristics (age
55.3 years, duration of diabetes 7 years, HbA1c 8.36%) and study results. Costs were
derived from published sources and expressed in 2010 UK Pounds. A discount rate
of 3.5 % was applied to both costs and outcomes. Various sensitivity analyses were
performed. RESULTS: EQW treatment was projected to improve quality-adjusted
life expectancy by 0.18 quality-adjusted life years (QALYs) (95% confidence interval
0.10 to 0.25) and life expectancy by 0.16 years (95% confidence interval 0.07 to 0.26)
versus exenatide BID. EQW was associated with delayed onset of any diabetes-
related complication versus exenatide BID by almost 6 months on average. Due to
the lower incidence of diabetes-related complications during treatment with EQW,
and hence reduction in their treatment costs, EQW was associated with direct
medical cost savings (difference of -£305, 95% confidence interval -£715 to £35).
EQW was therefore projected to be dominant versus exenatide. This result was
robust to all sensitivity analysis. CONCLUSIONS: Based on DURATION-1 and 5,
EQW was projected to be less costly and more effective than exenatide BID over a
patients’ lifetime in the UK setting.
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OBJECTIVES: The World Health Organization has recognized diabetes and other
selected chronic health conditions are at an epidemic level all of which can be
impacted by weight. The purpose of this project was to evaluate the role of diabetes
and Body Mass Index (BMI) on total medical expenses. METHODS: The Medical
Expenditure Panel Survey (MEPS) is publically available database providing nation-
ally representative estimates of health care use, expenditures, sources of payment,
and health insurance coverage for the US population. Analysis of the survey data
utilized design-based methods that utilized the complex survey stratification and
weighting. Regression was utilized to determine the effect of diabetes and BMI
class on total medical expenses in 2008, with inclusion of age, gender, race/ethnic-
ity, and insurance status as additional covariates. Models with and without two-
way interactions were performed. Summary statistics are presented as mean 
standard error. RESULTS: All adults (18 years; n22,128) were included, and av-
erage 2008 medical expenses were estimated at $4493  105. All variables in the
model were significant (p0.001), and adjusting for these factors, patients with
diabetes had an average medical expense of $4,512 410 higher than those without
diabetes. Across both cohorts, the morbid obese (BMI 40) had significantly higher
covariate adjusted medical expenses than normal (18.5 BMI25; $1340  414;
p0.001) and overweight (25 BMI30; $1517  420; p0.001) individuals,
whereas differences with obese (30 BMI40; $784  439; p0.08) and under-
weight (BMI18.5; -$88  754; p0.91) were not significant. CONCLUSIONS: Both
diabetes and high BMI are independently associated with significantly higher med-
ical expenses, and appear to be generally an additive effect. Increase in BMI was
associated with significantly higher medical costs even without diabetes. Morbidly
obese patients with diabetes had annual expenses averaging $12,004.
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OBJECTIVES: To model and evaluate consequences of enhanced treatment of type
2 diabetes mellitus on cost, life expectancy and development of complications in
the Bulgarian health care system. METHODS: The extensively published and vali-
dated CORE Diabetes Model was used to perform lifetime simulations for the rep-
resentative diabetic patient in Bulgaria diagnosed at 55 years. The analysis com-
pared two alternative treatment scenarios with current standards of care. In the
first alternative scenario the model examined the human and economic costs of
10% reduction in the risk factors for developing diabetes related complications. In
the second scenario consequences of treating to targets set in American Diabetes
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